by Gonzalo Payan | Sep 1, 2021
MAX BioPharma is pleased to announce that it has been awarded an SBIR Direct-to-Phase II grant from the NIH (NIAMS) titled: “Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion” (R44AR079335-01). With limited options on the market, the medical...by Gonzalo Payan | Sep 1, 2021
MAX BioPharma scientists, along with its UCLA colleagues, publish new paper titled “Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice” as they progress their fibrotic disorders program...by Gonzalo Payan | Feb 2, 2021
In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, MAX BioPharma scientists have identified new substances with antiviral activity against the novel coronavirus, SARS-CoV-2, the virus that caused the ongoing...by Gonzalo Payan | Aug 27, 2020
We are very pleased to announce the award of a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in support of our drug development program for Nonalcoholic Steatohepatitis (NASH),...by Gonzalo Payan | Mar 5, 2020
MAX BioPharma, Inc. recently published an article describing its anti-tumorigenic oxysterol lead compound, Oxy210, in the peer-reviewed journal, Cells. (https://www.mdpi.com/2073-4409/8/10/1297/pdf). Oxy210 is derived from the Company’s Oxysterol...